2-(4-甲酰基-3-羟基苯基)乙酸甲酯 | 1257397-40-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(4-甲酰基-3-羟基苯基)乙酸甲酯
• 英文名称: methyl 2-(4-formyl-3-hydroxyphenyl)acetate
• 英文别名: Methyl 2-(4-formyl-3-hydroxyphenyl)acetate
• CAS: 1257397-40-2
• 化学式: C₁₀H₁₀O₄
• 分子量: 194.187
• InChiKey: SVYFCXXBORRNPX-UHFFFAOYSA-N

物化性质

• 沸点：
  309.1±27.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-(4-甲酰基-3-羟基苯基)乙酸甲酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 水 、 碳酸氢钠 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 二氯甲烷 、 水 、 2,3,4-三氟甲苯 为溶剂， 反应 2.17h， 生成 (4'-fluoro-6-{(4-fluorophenyl)[4-(trifluoromethyl)piperidin-1-yl]methyl}biphenyl-3-yl)acetic acid
  参考文献：
  名称：

  Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator

  摘要：

  We have investigated a novel series of acid-derived gamma-secretase modulators as a potential treatment of Alzheimer's disease. Optimization based on cellular potency and brain pharmacodynamics after oral dosing led to the discovery of 10a (BIIB042). Compound 10a is a potent gamma-secretase modulator, which lowered A beta 42, increased A beta 38, but had little to no effect on A beta 40 levels both in vitro and in vivo. In addition, compound 10a did not affect Notch signaling in our in vitro assessment. Compound 10a demonstrated excellent pharmacokinetic parameters in multiple species. Oral administration of 10a significantly reduced brain A beta 42 levels in CF-1 mice and Fischer rats, as well as plasma A beta 42 levels in cynomolgus monkeys. Compound 10a was selected as a candidate for preclinical safety evaluation.

  DOI：

  10.1021/ml200175q
• 作为产物：
  描述：

  聚合甲醛 、 3-羟基苯乙酸甲酯 在 三乙胺 、 magnesium chloride 作用下， 以 乙腈 为溶剂， 反应 1.92h， 以9%的产率得到2-(4-甲酰基-3-羟基苯基)乙酸甲酯
  参考文献：
  名称：

  [EN] CARBOXYLIC ACID-CONTAINING COMPOUNDS, DERIVATIVES THEREOF, AND RELATED METHODS OF USE
  [FR] COMPOSÉS CONTENANT DE L'ACIDE CARBOXYLIQUE, LEURS DÉRIVÉS ET PROCÉDÉS D'UTILISATION ASSOCIÉS

  摘要：

  本文件描述了调节γ-分泌酶（例如，改变γ-分泌酶的切割模式）的化合物。还公开了包含这些化合物的药物组合物、调节γ-分泌酶活性的方法，以及使用本文件描述的化合物治疗阿尔茨海默病的方法。

  公开号：

  WO2010138901A1

文献信息

• [EN] CARBOXYLIC ACID-CONTAINING COMPOUNDS, DERIVATIVES THEREOF, AND RELATED METHODS OF USE<br/>[FR] COMPOSÉS CONTENANT DE L'ACIDE CARBOXYLIQUE, LEURS DÉRIVÉS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：BIOGEN IDEC INC

  公开号：WO2010138901A1

  公开（公告）日：2010-12-02

  Compounds that modulate gamma secretase (e.g., alter the cleavage pattern of gamma secretase) are described herein. Also disclosed are pharmaceutical compositions, methods of modulating the activity of gamma secretase, and methods of treating Alzheimer's Disease using the compounds described herein.

  本文件描述了调节γ-分泌酶（例如，改变γ-分泌酶的切割模式）的化合物。还公开了包含这些化合物的药物组合物、调节γ-分泌酶活性的方法，以及使用本文件描述的化合物治疗阿尔茨海默病的方法。
• Discovery of 4-aminomethylphenylacetic acids as γ-secretase modulators via a scaffold design approach
  作者：Zhili Xin、Hairuo Peng、Andrew Zhang、Tina Talreja、Gnanasambandam Kumaravel、Lin Xu、Ellen Rohde、Mi-yong Jung、Melanie N. Shackett、David Kocisko、Sowmya Chollate、Anthone W. Dunah、Pamela A. Snodgrass-Belt、H. Moore Arnold、Arthur G. Taveras、Kenneth J. Rhodes、Robert H. Scannevin

  DOI：10.1016/j.bmcl.2011.10.047

  日期：2011.12

  Starting from literature examples of nonsteroidal anti-inflammatory drugs (NSAIDs)-type carboxylic acid gamma-secretase modulators (GSMs) and using a scaffold design approach, we identified 4-aminomethylphenylacetic acid 4 with a desirable gamma-secretase modulation profile. Scaffold optimization led to the discovery of a novel chemical series, represented by 6b, having improved brain penetration. Further SAR studies provided analog 6q that exhibited a good pharmacological profile. Oral administration of 6q significantly reduced brain A beta 42 levels in mice and rats. (C) 2011 Elsevier Ltd. All rights reserved.
• Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator
  作者：Hairuo Peng、Tina Talreja、Zhili Xin、J. Hernan Cuervo、Gnanasambandam Kumaravel、Michael J. Humora、Lin Xu、Ellen Rohde、Lawrence Gan、Mi-young Jung、Melanie N. Shackett、Sowmya Chollate、Anthone W. Dunah、Pamela A. Snodgrass-belt、H. Moore Arnold、Arthur G. Taveras、Kenneth J. Rhodes、Robert H. Scannevin

  DOI：10.1021/ml200175q

  日期：2011.10.13

  We have investigated a novel series of acid-derived gamma-secretase modulators as a potential treatment of Alzheimer's disease. Optimization based on cellular potency and brain pharmacodynamics after oral dosing led to the discovery of 10a (BIIB042). Compound 10a is a potent gamma-secretase modulator, which lowered A beta 42, increased A beta 38, but had little to no effect on A beta 40 levels both in vitro and in vivo. In addition, compound 10a did not affect Notch signaling in our in vitro assessment. Compound 10a demonstrated excellent pharmacokinetic parameters in multiple species. Oral administration of 10a significantly reduced brain A beta 42 levels in CF-1 mice and Fischer rats, as well as plasma A beta 42 levels in cynomolgus monkeys. Compound 10a was selected as a candidate for preclinical safety evaluation.